advanc
techniqu
fi
eld
diagnost
microbiolog
made
amaz
progress
past
two
decad
due
larg
technolog
revolut
molecular
aspect
microbiolog
particular
rapid
molecular
method
nucleic
acid
ampli
fi
cation
character
combin
autom
userfriendli
softwar
signi
fi
cantli
broaden
diagnost
capabl
modern
clinic
microbiolog
laboratori
molecular
method
nucleic
acid
ampli
fi
cation
test
naat
rapidli
develop
introduc
clinic
laboratori
set
inde
everi
section
clinic
microbiolog
laboratori
includ
bacteriolog
mycolog
mycobacteriolog
parasitolog
virolog
bene
fi
ted
advanc
techniqu
rapid
develop
adapt
molecular
techniqu
interpret
relev
result
produc
molecular
method
lag
somewhat
behind
purpos
chapter
review
discuss
interpret
relev
result
produc
advanc
molecular
techniqu
moreov
chapter
address
myth
naat
myth
markedli
fl
uenc
interpret
relev
result
two
aspect
sensit
analyt
determin
limit
detect
given
specimen
diagnosticclin
determin
percentag
target
patient
true
posit
popul
naat
possess
excel
analyt
sensit
reach
ten
copi
target
genom
per
reaction
made
naat
essenti
detect
microbi
pathogen
specimen
cerebrospin
fl
uid
csf
may
extrem
low
microbi
load
howev
certain
situat
sensit
naat
inferior
convent
cultur
techniqu
larg
volum
specimen
easili
evalu
exampl
includ
blood
cultur
sputum
cultur
mycobacterium
tuberculosi
current
naat
usual
perform
use
small
volum
process
specimen
greatli
improv
sensit
naat
remain
lower
convent
cultur
techniqu
current
naat
design
monoplex
format
ie
one
primer
set
one
speci
fi
c
microbi
pathogen
although
use
multiplex
pcr
ampli
fi
cation
techniqu
increas
clinic
diagnost
fi
eld
multiplex
method
account
minor
molecular
test
convent
microbi
cultur
techniqu
chocol
agar
plate
mix
cell
line
would
allow
recoveri
mani
differ
pathogen
andor
multipl
pathogen
present
test
specimen
perspect
diagnost
sensit
monoplex
naat
may
suf
fi
cientli
high
sinc
detect
one
pathogen
test
rather
mani
differ
pathogen
andor
multipl
pathogen
term
realtim
pcr
indic
pcr
procedur
nucleic
acid
ampli
fi
cation
ampli
fi
cation
product
detect
happen
simultan
realtim
pcr
method
often
incorpor
fret
procedur
allow
amplicon
detect
identi
fi
cation
occur
real
time
relat
nucleic
acid
ampli
fi
cation
avoid
carryov
amplicon
contamin
sinc
reaction
occur
close
system
moreov
realtim
pcr
allow
accur
quanti
fi
cation
nucleic
acid
howev
naat
base
realtim
pcr
method
necessarili
sensit
naat
contrast
due
nonspeci
fi
c
spontan
fret
procedur
realtim
pcr
assay
may
less
sensit
due
rais
cutoff
valu
arithmet
spontan
increas
fl
uoresc
background
emiss
interfer
exponenti
speci
fi
c
energi
emiss
simultan
detect
procedur
produc
potenti
falseposit
result
overcom
nonspeci
fi
c
issu
system
either
increas
cycl
threshold
ct
cutoff
valu
decreas
cycl
number
ampli
fi
cation
result
decreas
sensit
realtim
pcr
provid
nice
quali
fi
cation
procedur
wide
rang
cover
howev
ideal
qualit
assay
measur
object
criteria
determin
cutoff
point
problemat
microbi
load
test
specimen
extrem
low
exampl
hsv
chlamydia
pneumonia
detect
csf
specimen
realtim
pcr
object
sensit
comparison
end
detect
pcr
procedur
later
procedur
separ
detect
identi
fi
cation
use
ampli
fi
cation
addit
signal
ampli
fi
cation
eg
antigenantibodi
link
incorpor
enhanc
test
sensit
naat
often
consid
use
test
assess
therapeut
ef
fi
caci
howev
true
naat
detect
microbi
organismspeci
fi
c
nucleic
acid
therefor
posit
naat
result
occur
aliv
dead
microorgan
particularli
true
pathogen
protect
cell
wall
best
exampl
detect
tuberculosi
dna
sputum
dead
microbi
pathogen
dna
remain
undegrad
due
fatti
acidrich
cell
wall
unlik
result
functionbas
test
method
mycobacteri
cultur
clinic
set
posit
pcr
result
antituberculosi
therapi
necessarili
mean
treatment
failur
therefor
dnatarget
naat
usual
consid
test
cure
also
true
sexual
transmit
pathogen
chlamydia
trachomati
neisseria
gonorrhea
although
dnatarget
naat
use
therapeut
monitor
mrnatarget
naat
may
use
assess
antimicrobi
treatment
therapi
exampl
applic
mrnatarget
naat
demonstr
monitor
tuberculosi
therapi
antitb
therapi
regimen
select
larg
empir
treatment
may
modi
fi
ed
week
month
later
result
antimicrobi
suscept
test
becom
avail
halflif
bacteri
mrna
extrem
short
compar
rrna
genom
dna
molecular
assay
target
mycobacteri
mrna
better
fl
ect
mycobacteri
viabil
abil
mrnabas
assay
distinguish
viabl
nonviabl
organ
demonstr
assay
use
monitor
ef
fi
caci
antitb
therapi
convent
microbiolog
method
gener
direct
object
term
interpret
result
blood
cultur
posit
staphylococcu
aureu
strongli
suggest
patient
staphylococc
bacteremia
posit
hepat
igm
antibodi
detect
serum
impli
recent
infect
caus
viru
howev
posit
naat
result
somewhat
indirect
subject
sinc
exact
mean
posit
naat
result
microbespeci
fi
c
nucleic
acid
exist
test
specimen
caus
contamin
colon
andor
infect
even
infect
establish
either
acut
chronic
infect
higher
sensit
may
alway
clinic
relev
one
good
exampl
seen
varicellazost
viru
vzv
previous
posit
vzv
result
either
dfa
cultur
would
interpret
vzv
caus
pathogen
would
consid
clinic
relev
pcrbase
naat
increas
vzv
detect
sever
hundredfold
posit
naat
result
vzv
skin
mucos
lesion
specimen
may
unclear
exact
caus
relationship
viru
infect
bloodstream
infect
long
recogn
among
sever
manifest
bacteri
diseas
fi
rst
describ
keefer
sentinel
paper
clinic
signi
fi
canc
bacteremia
import
rapid
diagnosi
bloodstream
infect
argu
serv
illustr
mani
issu
involv
interpret
relev
advanc
techniqu
diagnost
microbiolog
keefer
point
clinic
relev
bacteremia
blood
cultur
well
establish
evalu
febril
patient
sinc
techniqu
pitfal
blood
cultur
well
clinic
implic
posit
blood
cultur
well
document
surprisingli
molecular
nonculturebas
method
rapid
diagnosi
bloodstream
infect
wide
evalu
studi
along
earlier
studi
blood
cultur
illustr
import
point
regard
limit
molecular
assay
diagnos
bloodstream
infect
describ
detect
circul
microbi
dna
ie
dnaemia
per
se
new
diagnost
paramet
may
may
repres
presenc
viabl
microorgan
blood
exampl
interpret
dnaemia
coagulaseneg
staphylococci
problemat
due
falseposit
rate
rang
contrast
interpret
dnaemia
ehrlichia
speci
problem
due
trueposit
rate
interpret
dnaemia
also
problem
studi
dnaemia
detect
pcr
blood
cultur
number
falseposit
pcr
result
consid
clinic
signi
fi
cant
base
either
retrospect
chart
review
subsequ
isol
pathogen
relev
clinic
specimen
clearli
continu
clinic
investig
microbi
dnaemia
sepsi
critic
ill
need
provid
better
understand
biolog
microbi
circul
dna
underpin
molecular
diagnost
techniqu
anoth
import
issu
molecular
diagnost
techniqu
need
molecular
detect
resist
determin
antimicrobi
suscept
test
recogn
import
con
fi
rming
suscept
chosen
empir
antimicrobi
agent
well
detect
resist
individu
microbi
isol
current
method
antimicrobi
suscept
test
continu
base
part
detect
microbi
growth
lack
growth
presenc
antimicrobi
agent
test
direct
detect
resist
gene
molecular
method
pcr
date
limit
due
fact
rel
resist
gene
fi
rmli
associ
phenotyp
resist
exampl
resist
gene
associ
phenotyp
resist
found
gramposit
cocci
includ
meca
vana
vanb
contrast
lack
consensu
sequenc
among
acetyltransferas
adenyltransferas
gene
gramneg
bacilli
make
molecular
detect
aminoglycosid
resist
dif
fi
cult
although
molecular
method
antimicrobi
suscept
test
ascend
phenotyp
method
determin
level
suscept
bacteri
isol
antimicrobi
agent
like
remain
clinic
relev
mani
year
volum
blood
cultur
known
import
variabl
blood
cultur
number
microorgan
blood
may
small
typic
adult
fewer
cfuml
may
less
cfuml
septic
neonat
sizeabl
subset
less
cfuml
clearli
volum
blood
test
molecular
method
also
import
moreov
poisson
distribut
microorgan
evenli
distribut
increas
likelihood
sampl
small
volum
blood
miss
microorgan
caus
sepsi
volumerel
issu
may
explain
lower
sensit
seen
molecular
method
seen
convent
blood
cultur
studi
neonat
sepsi
poisson
distribut
may
explain
moder
concord
blood
cultur
molecular
method
report
studi
postsurg
sepsi
adult
sampl
blood
collect
assess
bacteremia
andor
fungemia
whether
analysi
done
blood
cultur
molecular
method
contamin
microorgan
skin
venipunctur
andor
indwel
vascular
devic
blood
obtain
devic
falseposit
blood
cultur
recogn
troublesom
issu
decad
contamin
less
import
molecular
method
tuberculosi
remain
one
import
public
health
issu
world
tuberculosi
result
approxim
million
death
year
number
new
case
worldwid
estim
nine
million
higher
time
histori
yet
control
treatabl
infect
handicap
recent
lack
new
diagnost
test
detect
tuberculosi
drug
resist
develop
molecular
assay
detect
tuberculosi
well
simultan
detect
resist
isoniazid
andor
rifampin
promis
greatli
assist
tb
control
effort
although
import
limit
molecular
method
must
understood
interpret
result
consid
relev
molecular
techniqu
inde
none
molecular
method
elimin
need
mycobacteri
cultur
requir
laboratori
infrastructur
accommod
molecular
test
speci
fi
c
limit
molecular
method
interpret
relev
describ
current
number
differ
molecular
assay
detect
presenc
tuberculosi
sputum
includ
pcr
transcriptionmedi
ampli
fi
cation
loopmedi
isotherm
ampli
fi
cation
xpert
mtbrif
comparison
mycobacteri
cultur
molecular
assay
possess
sensit
approach
gener
molecular
method
work
better
smearposit
smearneg
sputum
specimen
none
sensit
mycobacteri
cultur
sensit
patient
smearneg
sputum
increas
use
bronchial
aspir
bronchial
lavag
fl
uid
still
sensit
mycobacteri
cultur
current
number
differ
molecular
assay
detect
gene
mutat
associ
resist
particular
antituberculosi
drug
alway
gap
basic
research
clinic
applic
drugresist
mechan
remain
unknown
new
resistancerel
mutat
emerg
addit
molecular
assay
basic
includ
dna
ampli
fi
cation
step
categor
manner
ampli
fi
ed
dna
detect
except
sequenc
distinct
advantag
method
none
method
includ
sequenc
abl
detect
resist
strain
although
sequenc
come
closest
major
limit
molecular
method
except
sequenc
detect
known
mutat
de
fi
ned
site
region
design
depend
upon
known
mutat
advantag
sequenc
molecular
detect
mutat
drug
resist
seen
recent
report
center
diseas
control
prevent
studi
use
dna
sequenc
detect
resist
fi
rstline
antituberculosi
drug
isoniazid
rifampin
pyrazinamid
ethambutol
secondlin
drug
amikacin
capreomycin
kanamycin
cipro
fl
oxacin
fl
oxacin
molecular
data
compar
phenotyp
data
sensit
speci
fi
citi
valu
fi
rstline
secondlin
drug
loci
gener
excel
support
use
dna
sequenc
detect
drug
resist
tuberculosi
complex
although
uncommon
misidenti
fi
cation
report
molecular
assay
tuberculosi
one
report
case
patient
present
inguin
lymphadenopathi
well
erythema
nodosumlik
lesion
leg
forearm
biopsi
enlarg
inguin
lymph
node
demonstr
caseat
granulomata
numer
acidfast
bacilli
ziehlneelsen
stain
portion
node
sent
mycobacteri
cultur
molecular
analysi
addit
skin
biopsi
forearm
nodul
done
reveal
acidfast
bacilli
morpholog
typic
mycobacterium
lepra
diagnosi
leprosi
made
base
clinic
present
skin
biopsi
result
howev
lymph
node
sent
mycobacteri
cultur
molecular
analysi
posit
genprob
ampli
fi
ed
tuberculosi
direct
mtd
test
bbl
although
leprosi
still
consid
correct
diagnosi
due
clinic
present
skin
biopsi
fi
nding
possibl
patient
also
tuberculosi
could
rule
cultur
result
known
therefor
patient
treat
leprosi
tuberculosi
cultur
week
well
addit
pcr
test
lymph
node
materi
tuberculosi
report
neg
root
caus
analysi
done
order
investig
misidenti
fi
cation
lepra
cultur
materi
obtain
nation
hansen
diseas
program
louisiana
state
univers
mycobacteri
organ
test
genprob
mtd
test
posit
concentr
organ
per
ml
indetermin
concentr
organ
per
ml
investig
conclud
high
concentr
lepra
clinic
specimen
could
lead
falseposit
result
genprob
mtd
test
doubt
respiratori
tract
infect
caus
tuberculosi
also
consider
clinic
import
lower
respiratori
tract
infect
continu
lead
caus
death
due
infecti
diseas
unit
state
well
worldwid
hospitalacquir
pneumonia
consid
one
dif
fi
cult
treatment
challeng
infecti
diseas
part
result
cultur
antimicrobi
suscept
test
take
h
longer
viral
respiratori
tract
infect
caus
pathogen
sever
acut
respiratori
syndrom
coronaviru
sarscov
novel
fl
uenza
viru
caus
epidem
viral
pneumonia
patient
respiratori
failur
signi
fi
cant
risk
mortal
respiratori
tract
infect
also
import
ambulatori
set
document
overus
antimicrobi
agent
patient
popul
despit
obviou
clinic
import
respiratori
tract
infect
diagnosi
lower
respiratori
tract
infect
alway
problemat
due
larg
part
issu
relat
optim
collect
evalu
sputum
diagnost
valu
detect
tuberculosi
sputum
recogn
earli
evalu
sputum
becam
cornerston
diagnosi
tuberculosi
postmortem
studi
late
earli
establish
role
microorgan
streptococcu
pneumonia
haemophilu
fl
uenza
aureu
klebsiella
pneumonia
nontubercul
infect
respiratori
tract
use
gram
stain
describ
microscop
examin
sputum
follow
introduct
sputum
cultur
diagnosi
bacteri
pneumonia
note
earli
report
describ
sputum
cultur
recognit
collect
sputum
import
exampl
hast
nile
public
point
exud
form
portion
respiratori
tract
normal
steril
may
collect
treat
way
prevent
contamin
investig
de
fi
ne
clean
sputum
ie
one
contain
two
three
type
bacteria
free
buccal
squamou
cell
dirti
sputum
ie
one
contain
vari
bacteri
fungoid
fl
ora
buccal
squamou
cell
readili
recogn
microscop
examin
also
state
dirti
sputum
suitabl
bacteri
examin
discard
second
third
clean
specimen
patient
luetscher
opin
paper
patient
instruct
expector
bottl
dish
certain
come
boot
also
made
understand
littl
want
littl
must
choic
astut
observ
remain
relev
centuri
later
clearli
pitfal
collect
expector
sputum
specimen
suitabl
microscop
examin
cultur
recogn
earli
twentieth
centuri
pitfal
articul
address
particular
contamin
microorgan
present
upper
respiratori
tract
ie
nasaloralpharyng
region
consid
major
issu
expector
sputum
pitfal
number
altern
method
use
obtain
better
sputum
specimen
bronchoscopi
although
introduc
earli
twentieth
centuri
use
occas
aspir
pu
larger
airway
wide
use
obtain
sputum
microscopi
cultur
fi
beropt
bronchoscopi
becam
avail
fiberopt
bronchoscopi
also
result
use
bronchoalveolar
lavag
diagnos
acut
bacteri
pneumonia
method
adopt
obtain
uncontamin
sputum
includ
transtrach
aspir
percutan
needl
biopsi
openlung
biopsi
despit
continu
attempt
obtain
appropri
sputum
specimen
clinic
relev
use
sputum
cultur
continu
question
numer
report
inde
infecti
diseas
societi
americaamerican
thorac
societi
consensu
guidelin
manag
communityacquir
pneumonia
adult
recommend
pretreat
gram
stain
cultur
perform
good
qualiti
sputum
sampl
obtain
qualiti
perform
measur
collect
transport
process
sputum
sampl
assur
must
rememb
sputum
collect
weakest
link
chain
evid
provid
etiolog
diagnosi
pneumonia
assum
sputum
collect
done
correctli
next
issu
make
sure
microbi
pathogen
present
sputum
identi
fi
ed
surpris
molecular
assay
detect
character
microorgan
rapidli
emerg
clinic
microbiolog
laboratori
import
adjunct
tradit
cultur
method
quickli
realiz
molecular
assay
naat
offer
signi
fi
cant
advantag
convent
method
detect
mycoplasma
pneumonia
legionella
speci
chlamydia
speci
moreov
three
respiratori
pathogen
requir
concomit
suscept
test
result
clinic
isol
similarli
advantag
naat
laboratori
diagnosi
pertussi
recogn
earli
pcr
test
consid
cdc
import
tool
diagnosi
pertussi
especi
set
current
resurg
pertussi
diseas
provid
time
result
improv
sensit
cultur
inher
problem
associ
detect
identi
fi
cation
respiratori
virus
cultur
andor
serolog
method
also
result
earli
applic
molecular
assay
rapid
detect
character
respiratori
virus
userdevelop
commerci
molecular
method
quickli
evolv
allow
rapid
identi
fi
cation
multipl
common
viral
pathogen
caus
respiratori
tract
infect
addit
identi
fi
cation
viral
respiratori
pathogen
appreci
rapid
molecular
assay
would
also
offer
signi
fi
cant
advantag
diagnos
recogn
bacteri
pulmonari
pathogen
caus
communityacquir
pneumonia
inde
initi
studi
rapid
molecular
assay
combin
convent
diagnost
method
demonstr
approach
increas
etiolog
diagnosi
lower
respiratori
tract
infect
consider
especi
true
patient
adequ
collect
sputum
interest
observ
naat
increas
diagnost
treatment
cost
final
diagnosi
hospitalacquir
pneumonia
anoth
potenti
area
use
rapid
molecular
assay
respiratori
pathogen
may
prove
use
current
clinic
trial
need
provid
evid
molecular
assay
best
well
molecular
inform
appli
clinic
set
clearli
limit
convent
sputum
cultur
method
diagnos
respiratori
tract
infect
also
limit
molecular
method
particular
collect
sputum
continu
import
aspect
diagnosi
lower
respiratori
tract
infect
even
molecular
assay
use
new
molecular
method
guarante
microbiolog
laboratori
receiv
optim
sputum
sampl
analyz
anoth
import
aspect
molecular
assay
diagnosi
respiratori
infect
method
clearli
go
reveal
complex
pulmonari
microbiom
inde
recent
applic
molecular
assay
reveal
divers
microbiota
previous
recogn
airway
patient
chronic
pulmonari
diseas
exampl
comprehens
pro
fi
ling
airway
bacteri
commun
accomplish
use
cultureindepend
microarray
rrna
phylochip
cohort
copd
patient
requir
ventilatori
support
antimicrobi
therapi
exacerbationrel
respiratori
failur
phylochip
analysi
demonstr
presenc
bacteri
taxa
repres
distinct
famili
includ
mani
previous
detect
airway
diseas
core
commun
bacteri
taxa
note
patient
mani
microorgan
known
pathogen
airway
diseas
given
fact
pulmonari
microbiom
complex
previous
appreci
obviou
question
becom
microorgan
colon
caus
infect
one
might
also
ask
real
differ
colon
versu
infect
airway
molecular
identi
fi
cation
bacteria
lower
airway
preterm
infant
reveal
earli
bacteri
colon
airway
divers
speci
occur
within
fi
rst
day
life
intub
preterm
infant
neonat
airway
colon
gramneg
bacilli
associ
cytokin
respons
well
sever
bronchopulmonari
dysplasia
etiolog
role
neonat
colon
children
noncyst
fi
brosi
bronchiectasi
unclear
time
molecular
method
may
provid
insight
pathogenesi
disord
similarli
etiolog
role
bacteri
colon
pathogenesi
chronic
obstruct
pulmonari
diseas
current
elucid
assist
molecular
method
extrem
sensit
molecular
method
naat
may
result
simultan
detect
multipl
pathogen
sputum
specimen
detect
multipl
pathogen
sputum
molecular
method
alreadi
report
communityacquir
pneumonia
mix
infect
frequent
seen
commonli
pneumonia
togeth
respiratori
viru
fi
nding
unexpect
number
studi
report
associ
viral
respiratori
tract
infect
invas
pneumococc
diseas
molecular
diagnost
method
employ
studi
respiratori
tract
infect
con
fi
rmed
etiolog
role
viral
respiratori
tract
infect
bacteri
pneumonia
import
issu
naat
whether
ampli
fi
cation
product
truli
repres
target
microorgan
molecular
method
employ
dna
sequenc
often
consid
complet
accur
sensit
speci
fi
citi
unfortun
case
varieti
technic
factor
fl
uenc
contamin
dna
sourc
sequenc
templat
select
primer
use
ampli
fi
cation
qualiti
basecal
softwar
method
use
compil
consensu
sequenc
multipl
forward
revers
reaction
inappropri
chosen
gene
target
region
result
falseposit
neg
insert
sequenc
element
found
sever
hundr
copi
bordetella
pertussi
genom
frequent
use
target
b
pertussi
detect
much
greater
analyt
sensit
assay
singlecopi
target
sequenc
pertussi
toxin
promot
howev
falseposit
result
report
due
smaller
copi
number
exist
nonpertussi
bordetella
speci
accuraci
assay
develop
often
appreci
nonmolecular
microbiologist
clinician
acut
diarrheal
ill
selflimit
viral
afebril
patient
present
wateri
nonbloodi
diarrhea
less
h
durat
microbiolog
investig
usual
unnecessari
contrast
patient
diarrheal
ill
last
one
day
especi
ill
accompani
fever
bloodi
stool
recent
antimicrobi
use
hospit
system
ill
microbiolog
evalu
diarrheal
stool
microbiolog
stool
evalu
enter
infect
mani
decad
reli
upon
analysi
bacteri
cultur
andor
microscopi
detect
ova
parasit
nosocomi
diarrhea
patient
histori
recent
use
antimicrobi
agent
prior
onset
diarrhea
microbiolog
stool
evalu
focu
diagnosi
toxigen
clostridium
dif
fi
cile
persist
diarrhea
patient
histori
intern
travel
microbiolog
stool
evalu
may
requir
special
select
differenti
agar
thiosulf
citrat
bile
salt
sucros
tscb
agar
vibrio
speci
final
norovirus
common
caus
nonbacteri
enter
worldwid
laboratori
diagnosi
norovirus
depend
detect
viru
particl
em
detect
viral
antigen
eia
detect
viral
rna
realtim
pcr
given
complex
convent
method
microbiolog
evalu
stool
specimen
patient
diarrheal
ill
surpris
determin
microbiolog
etiolog
enter
infect
remain
elus
goal
wonder
molecular
method
appli
diagnosi
acut
infecti
diarrhea
enter
infect
due
broad
rang
potenti
pathogen
virus
bacteria
protozoa
helminth
well
suit
multiplex
molecular
assay
inde
monoplex
multiplex
molecular
assay
mani
enter
pathogen
alreadi
describ
therefor
import
clinician
microbiologist
appreci
limit
molecular
assay
absenc
gold
standard
microbiolog
caus
enter
infect
mean
clinic
signi
fi
canc
detect
pathogen
may
alway
clear
although
convent
wisdom
suggest
one
main
pathogen
caus
enter
infect
patient
detect
multipl
pathogen
patient
challeng
think
apt
particularli
true
parasit
enter
infect
moreov
detect
rna
dna
stool
specimen
necessarili
mean
viabl
infecti
pathogen
molecular
assay
includ
highthroughput
sequenc
techniqu
begun
identifi
vast
commun
bacteria
inhabit
skin
gut
human
despit
method
human
gut
remain
rel
unexplor
complex
like
factor
use
naat
diagnos
enter
infect
reason
fl
uenc
contamin
dna
gut
microb
sequenc
templat
molecular
diagnosi
enter
infect
usual
begin
extract
nucleic
acid
specimen
specimen
gener
diarrheal
stool
sampl
extract
step
becom
critic
step
molecular
diagnost
process
stool
complex
mixtur
multipl
divers
nucleic
acid
ampli
fi
cation
inhibitor
investig
note
detect
given
target
reduc
sever
log
target
place
stool
mixtur
may
result
enter
pathogen
present
low
number
miss
reason
investig
use
molecular
method
follow
isol
potenti
enter
bacteri
pathogen
stool
addit
extract
dna
ova
parasit
may
dif
fi
cult
extract
dna
bacteria
concentr
ova
parasit
may
present
low
number
may
requir
microscop
evalu
pathogen
current
recogn
potenti
caus
enter
infect
mean
multiplex
pcr
luminex
bead
method
must
use
even
multiplex
approach
like
requir
use
diagnost
algorithm
use
sever
multiplex
assay
use
multiplex
assay
creat
sever
technic
problem
includ
dif
fi
culti
discrimin
multipl
target
singl
reaction
reduc
sensit
multiplex
assay
also
caus
problem
interpret
due
detect
multipl
pathogen
exampl
one
studi
reexamin
stool
sampl
use
pcr
found
detect
rate
increas
viral
bacteri
pathogen
detect
rate
multipl
pathogen
also
increas
molecular
assay
due
high
sensit
may
detect
low
level
enter
pathogen
unclear
clinic
signi
fi
canc
exampl
giardia
speci
known
occur
stool
high
rate
person
without
diarrhea
therefor
use
quantit
pcr
method
may
need
order
provid
inform
use
interpret
clinic
signi
fi
canc
assumpt
higher
burden
like
associ
diseas
ultim
relationship
higher
burden
symptom
diseas
need
veri
fi
ed
mani
enter
pathogen
relationship
yet
determin
antimicrobi
resist
increas
mani
bacteri
pathogen
like
happen
enter
pathogen
shigella
salmonella
campylobact
detect
resist
determin
may
necessari
futur
like
dif
fi
cult
stool
sampl
due
divers
microorgan
present
stool
use
molecular
assay
diagnos
tissu
infect
anoth
area
rapidli
evolv
exampl
molecular
assay
proven
quit
success
diagnosi
infecti
endocard
inde
number
fastidi
microorgan
caus
endocard
identi
fi
ed
use
molecular
assay
includ
tropheryma
whippelii
bartonella
quintana
bartonella
hensela
coxiella
burnetii
success
result
molecular
assay
includ
best
practic
guidelin
identi
fi
cation
dif
fi
culttocultur
pathogen
infect
endocard
molecular
assay
tissu
use
diagnos
necrot
fasciiti
caus
group
streptococci
cultur
neg
avail
final
molecular
assay
fungal
pathogen
also
wide
studi
potenti
use
diagnosi
fungal
tissu
infect
fungal
pathogen
identi
fi
ed
tissu
molecular
assay
includ
paracoccidioid
brasiliensi
histoplasma
capsulatum
coccidioid
immiti
blastomyc
dermatitidi
aspergillu
fumigatu
absidia
corymbifera
rhisopu
arrhizu
candida
speci
nnat
use
detect
varieti
dna
rna
viral
pathogen
formalinfi
xed
paraf
fi
nembed
ffpe
tissu
specimen
use
molecular
assay
diagnos
tissu
infect
increas
time
therefor
limit
molecular
assay
appreci
freshfrozen
tissu
best
molecular
test
avail
molecular
test
consid
time
biopsi
contrast
ffpe
tissu
often
tissu
avail
molecular
test
consid
afterthought
accordingli
one
import
limit
use
molecular
assay
diagnos
tissu
infect
consid
assay
time
biopsi
fresh
tissu
use
frozen
use
later
differ
sensit
pcr
test
seen
studi
fresh
nonembed
tissu
found
sensit
pcr
detect
fungi
versu
ffpe
tissu
reason
decreas
sensit
nucleic
acid
obtain
ffpe
tissu
frequent
damag
ie
crosslink
may
contain
pcr
inhibitor
ffpe
tissu
must
use
housekeep
human
gene
must
ampli
fi
ed
control
wide
divers
potenti
microbi
pathogen
could
potenti
detect
tissu
readili
appar
pathogen
could
viral
bacteri
fungal
parasit
divers
greatli
fl
uenc
dna
target
pcr
primer
use
well
whether
monoplex
multiplex
pcr
method
use
exampl
speciesspeci
fi
c
identi
fi
cation
wide
rang
clinic
relev
fungal
pathogen
use
luminex
technolog
requir
three
differ
probe
fungal
pathogen
use
intern
transcrib
spacer
region
highli
variabl
among
genom
individu
fungal
speci
choic
dna
target
import
gener
molecular
assay
target
multicopi
gene
provid
greatest
sensit
ampli
fi
cation
method
provid
object
endpoint
assess
pdr
test
use
pcr
primer
import
exampl
insuf
fi
cient
variat
intern
transcrib
spacer
region
differenti
certain
speci
fungal
pathogen
therefor
analysi
region
consid
falseposit
result
describ
certain
primer
h
capsulatum
falseneg
result
found
c
immiti
ffpe
tissu
sensit
versu
fresh
tissu
sensit
suggest
primer
problem
degrad
inhibitor
final
estim
approxim
sequenc
genbank
misidenti
fi
ed
current
rel
commerci
kit
avail
molecular
test
use
tissu
specimen
laboratorydevelop
pcr
assay
tissu
use
must
evalu
veri
fi
ed
valid
laboratori
result
use
clinic
diagnosi
patient
care
dna
extract
ffpe
tissu
dif
fi
cult
requir
special
protocol
amount
dna
extract
usual
quit
small
report
method
show
ampli
fi
cation
success
rate
commerci
dna
extract
kit
evalu
one
method
takara
note
extract
dna
ffpe
tissu
sampl
housekeep
gene
could
ampli
fi
ed
moreov
method
costeffect
nonlabori
protocol
success
extract
rna
ffpe
specimen
depend
prompt
origin
tissu
process
welldevelop
extract
protocol
number
pathogen
scant
tissu
amount
dna
obtain
may
insuf
fi
cient
perform
pcr
assay
moreov
pathogen
often
randomli
distribut
tissu
ffpe
tissu
use
punch
biopsi
use
take
sampl
area
note
fl
ammat
andor
microorgan
stain
slide
tissu
block
stain
slide
mark
use
direct
locat
punch
biopsi
sampl
tissu
block
use
fresh
frozen
tissu
problemat
select
tissu
random
may
contain
microorgan
would
expect
molecular
assay
alreadi
note
detect
mix
infect
may
present
dif
fi
culti
interpret
result
particular
microbi
divers
endocard
note
cultivationindepend
molecular
techniqu
multipl
pathogen
detect
molecular
assay
also
report
fungal
infect
outcom
infecti
diseas
directli
relat
length
time
requir
identi
fi
cation
microbi
pathogen
recent
clinic
microbiolog
laboratori
handicap
convent
slow
multistep
culturebas
techniqu
requir
prolong
incub
time
mani
pathogen
abl
isol
other
clinician
unabl
clinic
judgment
diagnost
result
quickli
accur
identifi
pathogen
caus
infect
must
adopt
conserv
approach
involv
empir
therapi
broadspectrum
antimicrobi
agent
fortun
cumbersom
approach
rapidli
chang
introduct
molecular
diagnost
techniqu
inde
molecular
assay
naat
initi
revolut
fi
eld
diagnost
microbiolog
due
high
sensit
speci
fi
citi
rapid
test
turnaround
time
well
potenti
high
throughput
autom
molecular
assay
herald
diagnost
tool
millennium
howev
molecular
assay
also
bring
uncertainti
caus
falseposit
result
due
background
contamin
exogen
sourc
dna
exampl
one
studi
use
univers
rrna
pcr
assay
detect
eubacteri
dna
blood
sampl
healthi
subject
naat
also
may
give
falseneg
result
due
two
principl
reason
rel
small
sampl
requir
pcr
reaction
technic
problem
associ
pcr
process
moreov
result
molecular
assay
may
dif
fi
cult
interpret
appli
clinic
set
naat
increasingli
use
routin
clinic
microbiolog
laboratori
interpret
expect
dif
fi
cult
new
test
develop
complic
multiplex
assay
emerg
exampl
clinic
relev
posit
naat
paraf
fi
n
block
specimen
multipl
microbi
organ
found
specimen
need
care
interpret
use
molecular
assay
determin
usag
time
commun
clinician
microbiolog
laboratori
alway
suggest
whenev
interpret
need
final
clinic
microbiologist
clinician
must
acquir
work
knowledg
principl
diagnost
valu
limit
molecular
assay
